Role of activated oligoadenylatesynthetase–ribonuclease L pathways as a novel therapeutic target in psoriasis

Psoriasis (Pso) is predominantly an immune-mediated disease characterized by aberrant epidermal differentiation, surface scale formation, and marked cutaneous inflammation. Immune pathways activated in Pso include amplification of background immune circuits or induction of certain proinflammatory signaling pathways, otherwise latent in normal human skin. These changes include selective induction of antiviral innate immune response genes, differential expression of pathogen associated molecular pattern (PAMP) receptors, cell signaling and cell growth control pathways.